Biosplice Therapeutics, Inc. is a San Diego-based biotechnology company dedicated to restoring health by developing innovative therapies that target alternative splicing, a dynamic mechanism in human DNA that allows for the production of multiple protein variants with distinct functions. With a focus on osteoarthritis, oncology, and neurology, Biosplice aims to address the urgent need for effective treatments in these areas by harnessing the power of alternative splicing.
By targeting the CLK DYRK family kinases, Biosplice Therapeutics has gained fresh biological insights and unique chemical equity that enable therapeutic modulation of alternative splicing. This approach allows the company to selectively influence the selection of RNA splice-sites, offering a promising avenue for druggable targets in the command and control center of proteome diversification. With a mission to deliver first-in-class therapies, Biosplice is committed to making disruptive advances in the field of alternative splicing to improve patient outcomes and restore health.
Generated from the website